GlassScriptPhysician profile
Monte J Leidenix
NPI 1104814425
$1,022.44
in general payments reported to CMS, 2019-2025
15 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.45 · 2020: $59.27 · 2021: $105 · 2022: $186 · 2023: $176 · 2024: $248 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.67 | 2022-2025 | |
| Alcon Vision LLC | $209.22 | 2019-2024 | Argos |
| The Cameron-Ehlen Group, INC. | $119.16 | 2022-2023 | Tecnis Iol, Healon Pro, Tecnis Simplicity |
| Omeros Corporation | $62.82 | 2019-2021 | |
| Align Ophthalmics LLC | $52.65 | 2024 | |
| Rxsight INC | $49.45 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Rayner Intraocular Lenses Limited | $38.24 | 2022 | |
| Horizon Therapeutics Plc | $31.18 | 2022-2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $31.10 | 2019-2020 | |
| Harrow Eye, LLC | $30.28 | 2023-2024 | Iheezo |
| Novartis Pharmaceuticals Corporation | $26.23 | 2019 | |
| Oyster Point Pharma, INC. | $24.30 | 2022 | |
| Bausch & Lomb Americas INC. | $24.11 | 2025 | Xiidra, Miebo |
| Dompe US, INC. | $21.63 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monte Leidenix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.